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A protective association between bilirubin and atherosclerosis/ischemic heart disease clearly exists
in vivo. However, the relationship between bilirubin and in vivo oxidative stress parameters in a clinical
population remains poorly described. The aim of this study was to assess whether persons expressing
Gilbert syndrome (GS; i.e., unconjugated hyperbilirubinemia) are protected from thiol oxidation and to
determine if this, in addition to their improved lipoprotein proﬁle, could explain reduced oxidized
low-density lipoprotein (oxLDL) status in them. Forty-four matched GS and control subjects were
recruited and blood was prepared for the analysis of lipid proﬁle and multiple plasma antioxidants and
measures of oxidative stress. GS subjects possessed elevated plasma reduced thiol (8.0371.09 versus
6.7571.39 nmol/mg protein; Po0.01) and glutathione concentrations (12.772.39 versus
9.4472.45 mM; Po0.001). Oxidative stress status (reduced:oxidized glutathione; GSH:GSSG) was
signiﬁcantly improved in GS (0.4970.16 versus 0.3270.12; Po0.001). Protein carbonyl concentra-
tions were negatively associated with bilirubin concentrations and were signiﬁcantly lower in persons
with 440 mM bilirubin versus controls (o17.1 mmol/L; Po0.05). Furthermore, absolute oxLDL
concentrations were signiﬁcantly lower in GS subjects (Po0.05). Forward stepwise regression analysis
revealed that bilirubin was associated with increased GSH:GSSG ratio and reduced thiol concentrations,
which, in addition to reduced circulating LDL, probably decreased oxLDL concentrations within the
cohort. In addition, a marked reduction in total cholesterol concentrations in hyperbilirubinemic Gunn
rats is presented (Gunn 0.5770.09 versus control 1.6970.40 mmol/L; Po0.001), arguing for a novel
role for bilirubin in modulating lipid status in vivo. These ﬁndings implicate the physiological
importance of bilirubin in protecting from atherosclerosis by reducing thiol and subsequent lipoprotein
oxidation, in addition to reducing circulating LDL concentrations.
& 2012 Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Individuals with elevated circulating bilirubin concentrations
(including Gilbert syndrome; GS) are potently protected from
cardiovascular disease (CVD) [1,2] and cancer [3]. Persons with GS2
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Y-NC-ND license.have a circulating total bilirubin concentration of 417.1 mM,
due to additional TA repeats in the gene promoter for bilirubin
uridine diphosphate glucuronosyltransferase (UGT) 1A1, decreas-
ing expression [4]. Decreased UGT1A1 activity reduces bilirubin
conjugation and increases the circulating unconjugated bilirubin
concentration.
The mechanisms of in vivo protection in GS remain poorly
described and are limited to investigations studying inhibition of
lipid oxidation [5]. Reduced urinary excretion of bilirubin oxida-
tion products [6] and circulating advanced glycation end products
[7] in individuals with GS also suggest that bilirubin protects from
macromolecule modiﬁcation in vivo. Whether elevated unconju-
gated bilirubin concentrations are associated with reduced mar-
kers of lipid and protein oxidation, however, remains unknown.
Evidence to support the possibility of reduced protein and lipid
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animal studies [8,9]. Translation of these ﬁndings within clinical
cohorts, such as GS, provides a unique opportunity to reveal the
physiological importance of bilirubin, because circulating protein
and lipid oxidation markers are related to future CVD mortality,
which is reduced in GS [10].
Bilirubin, the pigment of jaundice, also causes neurotoxicity
in vitro, in newborns [11] and in adults with the rare condition of
Crigler–Najjar syndrome [12]. However, elevated circulating bilir-
ubin concentrations have been associated with protection from
neonatal hyperoxic exposure (and retinopathy of prematurity) in
both rodent [13] and human [14] studies. Despite these ﬁndings,
evidence to the contrary also exists and supports a popular debate
in this area [15,16]. Together, these ﬁndings show that bilirubin is
a molecule of diverse and currently unknown importance requir-
ing further exploration [17]. This study investigated whether GS
subjects possess improved reduced thiol and protein oxidation
biomarkers versus controls and explored the possible involve-
ment of bilirubin in modulating oxidative stress and lipid proﬁle
parameters using stepwise regression analysis.Methods
Subject recruitment
Subjects (18–63 years) were recruited from the general popula-
tion via Internet forums, e-mail advertisements, and posters. Subject
exclusion criteria included current or recent (2 weeks) bacterial or
viral infection, smoking, antioxidant supplementation, prescribed
medication (other than the contraceptive pill), excessive alcohol
consumption (48 standard drinks per week), elevated glucose or
serum liver enzyme activities, or presence of a lipid metabolism
disorder. The presence of a lipid metabolism disorder was deﬁned
using criteria developed by American [18,19] and European [20]
working parties (i.e., lipid metabolism disorder is deﬁned as
cholesterol 47.8 mmol/L and triglycerides 42.3 mmol/L or HDL
o0.9 mmol/L). Individuals were also excluded if they had a family
history of cardiovasculardisease/hypertension, diabetes, or hema-
tologic or liver disease. Blood pressure was measured using a
commercial sphygmomanometer (Homedics BPA-110-AU, Austra-
lia) and body mass index (BMI) was calculated using standard
digital scales and height assessment. Subjects were allocated to
the GS group if they possessed a previous diagnosis from a medical
practitioner and/or a circulating unconjugated bilirubin concen-
tration in excess of 17.1 mM (41 mg/dl) and normal serum liver
enzyme activities. Circulating plasma heme concentrations were
quantiﬁed to exclude individuals with overt hemolysis. In total 87
subjects were recruited and of these 44 (22 GS, 22 controls) were
matched for gender, age, and BMI. There were equal numbers of
female and male subjects in each group (11:11). The ethnicity of
the recruited cohort included Caucasian (80%) and Indo/Asian
(20%) individuals with similar distributions of ethnicity in each
group. The study was approved by the Human Ethics Research
Committee of Grifﬁth University (MSC/02/10/HREC).
Blood sample collection
Fasting blood samples (30 ml total) were collected into serum,
lithium heparin, and ethylenediaminetetraacetic acid vacutainers.
Samples were kept in the dark, on ice, and were processed within 1 h.
Animal experiments
Breeding pairs of heterozygote (genotyped) Gunn rats were
imported from the Rat Research and Resource Center (Columbia,MO, USA) and kept within an animal house facility at Grifﬁth
University (12-h light:dark cycle, constant temperature (22 1C)
and humidity (60%)). Rats had continuous access to standard
laboratory food pellets (Speciality Feeds, Glen Forrest, Australia)
and fresh water. Homozygous Gunn rat offspring were assumed
to possess jaundice at birth, were ear-tagged, and were housed
together with female littermate (nonjaundiced) controls after
weaning (all female, n¼7 and 5, respectively). Concentrations of
unconjugated bilirubin were measured in blood obtained from
the tail tip, during brief isoﬂurane anesthesia (3% in 100 O2;
1–2 L/min), at 21 day of age to conﬁrm the presence of jaundice.
Serum unconjugated bilirubin concentrations were analyzed
using high-performance liquid chromatography (HPLC) (see Bilir-
ubin and heme analysis). Nonjaundiced controls were assumed to
represent either heterozygous or wild-type Wistar rats that both
are UGT1A1 competent and possess unconjugated bilirubin con-
centrations approximating 1 mM. At 13 months of age (similar
relative age, in human years, to the clinical cohort) the animals
were anesthetized using intraperitoneal injection with pentobar-
bital sodium (concentration 60 mg/ml; 100 ml per 100 g). A mid-
line laparotomy was performed, including excision of the heart
(for other purposes), and approximately 5 ml of whole blood was
collected from the chest cavity using a syringe and prepared for
analysis of various biochemical parameters (see Sample prepara-
tion). All analytical procedures (see Serum biochemistry) were
identical to those used for clinical samples. All procedures were
approved by the Grifﬁth University Animal Ethics Research
Committee before experimentation (MSC/04/09).
Sample preparation
Plasma/serum was centrifuged (Thermo Scientiﬁc 5810R, Aus-
tralia) at 1500g for 15 min (4 1C). Aliquots were prepared imme-
diately and stored at 80 1C. Trichloroacetic acid (TCA; 10%, 1:1
ratio) was added to heparinized plasma aliquots, which were then
vortexed and centrifuged at 2200g for 5 min. Supernatant was
frozen at 80 1C for ascorbate and reduced/oxidized glutathione
analysis.
Bilirubin and heme analysis
The serum unconjugated bilirubin and heme concentrations
were quantiﬁed using HPLC and a photodiode array detector
(Waters, Australia) as previously described [5]. Slight variation
to this method included the use of a C18 reverse-phase HPLC
guard and analytical column (4.6150 mm, 3 mm; Phenomenex,
Australia) that was perfused at 1 ml min1. Extracted samples
(100 ml) were injected with a run time of 14 min in triplicate.
Unconjugated bilirubin (450 nm) and heme (400 nm) eluted at 12
and 8.5 min, respectively. Unconjugated bilirubin (0–100 mM) and
hemin (0–5 mM) served as external standards (Frontier Scientiﬁc,
Logan, UT, USA).
Serum biochemistry
Serum biochemistry including liver enzymes (alanine amino-
transferase, aspartate aminotransferase, g-glutamyltransferase),
glucose, uric acid (Thermo Scientiﬁc), antioxidant status including
Trolox equivalent antioxidant capacity (TEAC) [21], and ferric
reducing ability of plasma (FRAP) [22] was assessed using a Cobas
Mira automated analyzer (Roche, Switzerland). Lipid status
including assessment of total cholesterol, triglycerides, and
high-density lipoprotein were analyzed using commercially avail-
able kits on a COBAS Integra 400 blood chemistry analyzer (Roche
Diagnostics, Australia). Cholesterol analyses were conducted
using appropriate lipid standards (Calibrator for Automated
Table 1
Clinical characteristics of the recruited GS and control subjects (n¼22 per group).
Variable GS Control P value
Age (years) 32.6711.2 32.6710.9 0.860
BMI (kg/m2) 22.372.78 23.774.07 0.208
Glucose (mmol/L) 4.6970.38 4.8570.56 0.300
Total cholesterol (mmol/L) 4.4870.82 5.3171.29 0.014n
Triglycerides (mmol/L) 0.8370.31 1.0670.49 0.068nn
HDL (mmol/L) 1.7170.44 1.5970.43 0.345
LDL (mmol/L) 2.6170.67 3.5271.25 0.004n
HDL:LDL ratio 0.7170.25 0.5270.24 0.016n
Alanine aminotransferase
(IU/L)
17.878.78 19.2710.5 0.618
Aspartate aminotransferase
(IU/L)
17.575.99 16.876.09 0.708
g-Glutamyltransferase (IU/L) 21.7724.6 17.3710.6 0.440
Plasma heme (mmol/L)a 0.28 (0.21–0.38) 0.24 (0.16–0.32) 0.193
a Data presented as median (25–75% interquartile range).
n Signiﬁcant difference (Po0.05).
nn Trend approaching signiﬁcance (Po0.1).
Table 2
General characteristics, unconjugated bilirubin, and lipid status in female, middle-
aged (13 months old), littermate-matched Gunn (n¼7) and Wistar (n¼5) rats.
Variable Gunn Wistar P value
Mass (g) 208729 272727 0.002n
Unconjugated bilirubin (mmol/L) 41.478.39 1.0670.37 o0.001n
Total cholesterol (mmol/L) 0.5770.09 1.6970.40 o0.001n
Triglycerides (mmol/L) 1.4970.47 1.6570.43 0.574
HDL (mmol/L) 0.1270.05 1.0670.21 o0.001n
LDL (mmol/L) 0.1570.08 0.3070.26 0.194
HDL:LDL ratio 0.8770.45 6.7575.39 0.015n
n Signiﬁcant difference (Po0.05).
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Multi; Roche Diagnostics). The concentration of low-density
lipoprotein (LDL) cholesterol was calculated using the Friedewald
equation [23]. All analyses were conducted in duplicate.
Ascorbate analysis
Ascorbate concentrations were measured spectrophotometri-
cally using a 96-well plate reader (Multiskan FC, Thermo Scientiﬁc)
according to the method of Wei et al. [24] Supernatant from
TCA-precipitated samples (100 ml) was used to determine ascor-
bate concentrations. All samples were analyzed in triplicate and
ascorbic acid (from 0 to 20 mg/100 ml 5% TCA) was used as an
external standard.
Quantiﬁcation of reduced thiol/protein concentration
Reduced thiol concentrations were quantiﬁed in heparinized
plasma using a 96-well plate reader and 5,5-dithiobis(2-nitrobenzoic
acid) (DTNB) reagent. The concentration of TNB was quantiﬁed at
412 nm according to the method of Hawkins et al. [25] (in triplicate).
GSH (0–0.5 mM) served as an external standard. Thiol concentrations
were expressed initially in micromoles per liter and then converted to
nmol/mg of protein. Protein concentrations were determined accord-
ing to the bicinchoninic acid protein assay kit (Thermo Scientiﬁc).
Determination of protein carbonyls
Detection of protein carbonyls with 2,4-dinitrophenylhydra-
zine was modiﬁed from the original method of Levine et al. [26],
performed using an ELISA kit (Sapphire Biosciences, Australia)
and expressed in nmol/mg of protein.
Measurement of glutathione
Oxidized (GSSG) and reduced (GSH) glutathione concentra-
tions were measured using N-ethylmaleimide and o-phthalalde-
hyde (in triplicate) via a modiﬁed method of Hissin and Hilf [27]
using a Fluoroskan Ascent 96-well plate reader (Thermo Scientiﬁc).
The concentrations of GSH and GSSG in the samples were
determined using external standards ranging from 5 to 50 and
from 1.56 to 100 mM, respectively.
Oxidized low-density lipoprotein assay
A monoclonal antibody (mAb-4E6)-based ELISA kit (Dynamika
MH, Australia) was used for the quantiﬁcation of oxidized low-
density lipoprotein (oxLDL) in plasma. The assay was performed
in duplicate and expressed in U/L.
Statistical analysis
SigmaPlot software (version 11.0) was used to analyze all data.
Two-tailed, unpaired t tests (Student’s t test or Mann–Whitney
rank sum test) tested for differences in biochemical/clinical
variables between GS and control groups. Group data are reported
as means7standard deviation or median (25–75% interquartile
range). Pearson correlation tested the relationship between
unconjugated bilirubin and other dependent variables. Analysis
of the relationship between unconjugated bilirubin and protein
carbonyls was tested by dividing the group into quartiles each
containing approximately the same number of subjects. These
groups included persons with o10 (n¼11), 10.1–17.1 (n¼11),
17.2–40 (n¼15), and 440 mM (n¼7) unconjugated bilirubin. The
chosen cutoffs are representative of the concentrations deﬁning
increased (o10 mM) and decreased (410 mM) risk of CVD [1]and the approximate unconjugated bilirubin concentration asso-
ciated with visible jaundice (o40 mM versus 440 mM) [28]. All
antioxidant and blood lipid/glucose parameters were entered as
independent variables in a forward stepwise regression analysis
and their effects on oxidative stress-dependent variables were
analyzed. The level of signiﬁcance was set at Po0.05.Results
General biochemistry and lipid status
Serum glucose, liver enzyme concentrations, and the lipid
proﬁles of recruited subjects can be found in Table 1. GS subjects
possessed a reduced total cholesterol and LDL concentration in
addition to an increased HDL:LDL ratio (Po0.05 all variables)
compared to control subjects. Lipid variables (total cholesterol,
triglycerides, LDL, HDL:LDL ratio) were signiﬁcantly correlated or
tended to be correlated with bilirubin concentrations when the
cohort was investigated collectively (P¼0.03, 0.193, 0.01, 0.02,
respectively; Supplementary Figs. S1–S4). However, the signiﬁ-
cance of these relationships was lost when analyses within
control and GS groups were conducted (data not shown). Lipid
status in Gunn rat and littermate controls generally supported the
lipid biochemistry data in patients showing that hyperbilirubi-
nemic rodents possessed signiﬁcantly reduced total cholesterol
and HDL concentrations (Po0.001; Table 2). Hyperbilirubinemia
and hypocholesterolemia in Gunn rats were also associated with
signiﬁcantly reduced body mass (P¼0.002; Table 2).
Table 3
Serum/plasma antioxidant status in GS and controls (n¼22 per group).
Variable GS Control P value
Unconjugated bilirubin (mmol/L) 35.1718.2 10.372.89 o0.001n
Ferric reducing ability of plasma
(mmol Fe2þ/L)
1.1270.23 1.0270.19 0.129
Trolox equivalent antioxidant capacity
(mmol Trolox eq/L)
1.3670.13 1.3070.10 0.073
Uric acid (mmol/L) 266772.1 272775.6 0.793
Ascorbate (mg/ml) 6.0271.87 6.2271.71 0.710
Reduced thiols (mmol/L) 550764.2 493783.3 0.015n
Reduced thiols (nmol/mg protein) 8.0371.09 6.7571.39 0.002n
Reduced glutathione (mmol/L) 12.772.39 9.4472.45 o0.001n
Protein (mg/ml) 69.177.90 74.6712.0 0.083
n Signiﬁcant difference (Po0.05).
Fig. 1. Correlation between (A) reduced thiols (r¼0.412; Po0.01) and (B) GSH
(r¼0.444; Po0.01) and unconjugated bilirubin concentration in GS (K) and
control (J) subjects (n¼22 per group).
A.-C. Boon et al. / Free Radical Biology and Medicine 52 (2012) 2120–2127 2123Antioxidant status
Unconjugated bilirubin concentrations varied from 5.1 to
85.3 mM (0.3–5.0 mg/dl) in the whole cohort. Ascorbate, protein,
and uric acid concentrations were not signiﬁcantly different
between the groups; however, unconjugated bilirubin, reduced
thiol, and GSH concentrations were signiﬁcantly elevated in GS
(Po0.05, Table 3). Global measures of antioxidant status, TEAC,
and FRAP, which were nonsigniﬁcantly greater in GS (Table 3),
signiﬁcantly correlated with bilirubin concentrations (Po0.05;
Supplementary Figs. S5 and S6). Of the elevated antioxidants in
GS, reduced thiols and GSH were positively correlated with
circulating bilirubin concentrations (r¼0.412; Po0.01;
r¼0.444; Po0.01, respectively; Fig. 1).
Oxidative stress status
The GSH:GSSG ratio was signiﬁcantly greater in the GS group
(Table 4; Po0.001) and was positively correlated with bilirubin
concentration (r¼0.441, Po0.01; Fig. 2). The protein carbonyl
concentration was negatively associated with bilirubin (r¼0.505;
Po0.001) and was lower in persons with 440 mM bilirubin (n¼7),
versus non-GS subjects (Fig. 3). OxLDL concentrations decreased with
increasing bilirubin concentration (Fig. 4A). Elevated bilirubin was
also associated with reduced total and LDL cholesterol concentra-
tions (Supplementary Figs. S1 and S2). LDL cholesterol concentrations
effectively explained a large proportion of variance in oxLDL con-
centrations, which was signiﬁcantly decreased in GS (Fig. 4B,
Tables 4 and 5). Interestingly, when oxLDL concentrations were
expressed relative to the LDL concentration, the oxidative stress
marker was signiﬁcantly increased in GS (Table 4).
Forward stepwise regression analysis revealed that bilirubin
was the only independent variable, of those tested, that inﬂu-
enced reduced thiol concentration, GSH:GSSG ratio, and protein
carbonyl formation. Together, LDL, glucose, uric acid, and reduced
thiols explained more than 85% of the variance in oxLDL concen-
trations (Table 5).Table 4
Oxidative stress status in GS and control subjects (n¼22 per group).
Variable GS Control P value
Protein carbonyl (nmol/mg protein) 0.1870.04 0.1970.03 0.242
GSSG (mmol/L) 27.179.44 31.777.48 0.081
GSH:GSSG ratio 0.4970.16 0.3270.12 o0.001n
oxLDL (U/L) 16.272.24 18.673.57 0.011n
oxLDL (U/mmol LDL) 6.4771.27 5.6371.32 0.037n
n Signiﬁcant difference (Po0.05).Discussion
This report documents reduced baseline oxidative stress in GS,
which was speciﬁcally related to protection from thiol oxidation.
Reduced thiol concentration and GSH:GSSG ratio increased and
protein carbonyl concentration decreased in association with
increased circulating bilirubin concentration. By employing
forward stepwise regression analysis, multiple additional (and
cumulative) associations between independent variables (LDL,
glucose, uric acid, reduced thiols, and bilirubin) and biomarkers
Fig. 2. Correlation between GSH:GSSG ratio and unconjugated bilirubin concen-
tration in GS (K) and control (J) subjects (n¼22 per group; r¼0.441; Po0.01).
Fig. 3. (A) Correlation between protein carbonyl and unconjugated bilirubin
concentration (r¼0.505; Po0.001) in GS (K) and control (J) subjects (n¼22
per group). (B) Box plot showing the protein carbonyl concentration in unconju-
gated bilirubin quartiles (o10 mM unconjugated bilirubin, n¼11; 10.1–17.1 mM,
n¼11; 17.2–40 mM, n¼15; and 440 mM, n¼7). *Po0.05 versus all other groups.
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identiﬁed in this cohort. These data suggest bilirubin’s antiox-
idant effects are only one of many possible mechanisms leading
to reduced mortality in this population.
Bilirubin antioxidant effects
In this study, persons with GS tended to possess elevated
measures of global antioxidant capacity (Table 3), in agreement with
previous ﬁndings [5,10]. The difference in FRAP (nonthiol antioxidant
capacity) could be explained by the difference in bilirubin concentra-
tion alone (Table 3; 100 mM Fe2þ equivalents, each bilirubin
molecule reduces four ferric tripyridyltriazine radicals). The difference
in TEAC (Table 3; 60 mM Trolox equivalents; radical oxidizes all
major antioxidants in plasma) was greater than could be explained by
the difference in bilirubin concentration alone. Bilirubin can reduce
1.5 azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) radicals and,
therefore, the difference in bilirubin concentration between the
groups accounted for 37.5 mM Trolox equivalents. Therefore, it
was hypothesized that preserved thiol groups explained the addi-
tional TEAC antioxidant capacity in GS. Elevated reduced thiol
concentrations were subsequently conﬁrmed in GS (Table 3). These
ﬁndings are supported by elevated circulating sulfhydryl groups in a
small, unmatched Hungarian population of GS and control subjects
[29]. Plasma GSH levels were then explored and were found to be
signiﬁcantly elevated in GS (Table 3) and were also positively
correlated with circulating bilirubin concentrations (Fig. 1). These
data suggested dose-dependent protection from GSH oxidation in GS
and/or, intriguingly, that glutathione synthesis may be enhanced by
bilirubin [30].
Bilirubin is associated with reduced macromolecule oxidation and
modulates lipid proﬁle
Excessive radical production relative to antioxidant bioavailabil-
ity is fundamentally related to the likelihood of macromolecule
modiﬁcation and underpins past and present attempts to prevent/
treat diseases using antioxidant therapy [31]. To date, only Dennery
et al. [13] have shown that endogenously elevated bilirubin protectsfrom oxidative stress in rats exposed to hyperoxia. These data are
supported by animal studies showing that elevated endogenous or
exogenously applied bilirubin protects from bile acid- [32] and
hydroxyl radical- [33] induced oxidative stress, ex vivo.
Little evidence of bilirubin protection from in vivo protein
oxidation exists. Bilirubin protects albumin from in vitro oxidation
by superoxide, hydrogen peroxide, hypochlorite, and peroxy-
nitrite [34,35]. Reaction of superoxide with nitric oxide (NO) forms
peroxynitrite that can oxidize thiol groups and proteins [36,37].
Bilirubin scavenges both superoxide [34] and nitrite and inhibits the
release of NO [37,38] and, therefore, the formation of peroxynitrite.
Fig. 4. (A) Correlation between oxLDL and bilirubin concentration (r¼0.277;
P¼0.069). (B) OxLDL and LDL concentration (r¼0.879; Po0.001) in GS (K) and
control (J) subjects (n¼22 per group).
Table 5
Regression modeling of independent variables.
Dependent
variable
R2 value
LDL Glucose Uric
acid
Reduced
thiols
Bilirubin Total
GSH:GSSG – – – – 0.194 0.194
Reduced thiols – – – – 0.197 0.197
Protein carbonyls – – – – 0.255 0.255
OxLDL 0.772 0.037 0.035 0.015 – 0.859
R2 values represent the percentage (100) of variance that the independent
variables could explain in the dependent variable within the model.
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reaction of oxidation through the protein backbone [35], which leads
to inevitable terminal protein carbonyl formation. Protection of
proteins from oxidation is important for the maintenance of pro-
tein/enzyme function and for protection from a variety of diseases,
including CVD, via apolipoprotein B oxidation [39]. A meta-analysis
has concluded that a bilirubin concentration of below 10 mM
delineates a cutoff for increased risk of CVD in men [1]. Protein
carbonyl concentration is related to CVD [40]; however, we observed
no difference in carbonyl concentrations between the lowest three
bilirubin quartiles (0–10, 10.1–17.1, 17.2–40 mM). Despite this, dose-
dependent protection from protein carbonyl formation exists,supported by lower carbonyl concentrations in persons with
440 mM bilirubin (Fig. 3). These data suggest a molar ratio of
1:10 bilirubin:albumin is required to signiﬁcantly protect from
protein carbonyl formation in vivo.
In vitro evidence supports a role for bilirubin in protecting
lipids from various radical species [8]. A recent study by Tapan
et al. [41] demonstrated signiﬁcantly reduced oxLDL in GS com-
pared to controls. Indeed, we showed that oxLDL levels were
correlated with bilirubin (Fig. 4A); however, LDL was also corre-
lated with oxLDL concentrations (Fig. 4B). Clearly LDL concentra-
tion inherently affects the likelihood of LDL oxidation; however, so
would bilirubin and other antioxidants. Therefore, we employed
regression modeling to quantitate the effects of multiple indepen-
dent variables on dependent variables, including oxLDL. The
results showed that decreased LDL concentrations (in the entire
cohort) largely (77.2%) inﬂuenced oxLDL concentrations. However,
glucose, uric acid, and free thiol concentrations further and
signiﬁcantly explained the variance in oxLDL concentrations (total
prediction 85.9%). Regression modeling also showed bilirubin was
the only variable measured that inﬂuenced the concentration of
reduced thiols and, therefore, may assist in protecting LDL from
oxidation, by preserving thiol status. It should be noted, however,
that this effect is probably minor.
The signiﬁcant increase in oxLDL, when expressed relative to
LDL content in GS (Table 4), was an interesting and unexpected
ﬁnding of this study. Although the signiﬁcance of this ﬁnding to
atherogenesis is questionable (because absolute oxLDL concen-
trations were lower in GS), this ﬁnding suggests that circulating
LDL was more susceptible to oxidation in GS. This observation
is in disagreement with recent reports showing elevated circulat-
ing bilirubin improves resistance of plasma lipids and LDL
to oxidation, when quantiﬁed using lag-phase duration [5,42].
Interestingly however, when total oxidation after 6 h was quanti-
ﬁed relative to lipid content, we previously showed a trend
toward elevated lipid oxidation in GS samples (P¼0.166) [5].
A theoretical basis for such a conclusion was proposed by Stocker
and Ames [43], who hypothesized that bilirubin ditaurate could
also act as a peroxidase, liberating lipid peroxide radicals in the
presence of copper. Therefore, we speculate that additional
bilirubin in the plasma of GS probably delays the initiation of
copper-induced oxidation; however, it might result in additional
lipid peroxidation in the longer term as documented here.
Relationships between circulating bilirubin and lipid status have
been presented in previous studies, although these ﬁndings have
gone essentially unnoticed or have been published only recently. For
example, reduced circulating total cholesterol [41], LDL [44], trigly-
ceride concentrations [6], and BMI [45] and elevated HDL:LDL ratio
[5] have been documented in GS. Although these ﬁndings are by no
means consistent between all published studies [46,10] (because of
differences in subject matching and cohort characteristics), they
generally agree with ﬁndings in this cross-sectional, age-, gender-,
and BMI-matched study (see Table 1, Supplementary Figs. S1–S4).
A.-C. Boon et al. / Free Radical Biology and Medicine 52 (2012) 2120–21272126These data are further supported by clinical data showing lower
total cholesterol [47,48] and BMI [49,50] in persons with elevated
circulating bilirubin, in addition to signiﬁcant negative correlations
between lipid parameters and circulating bilirubin species [49,51].
We provide additional data supporting a possible role for
unconjugated bilirubin (or UGT1A1 activity) in reducing circulat-
ing total and HDL cholesterol concentrations in the hyperbilirubi-
nemic Gunn rat (Table 2). The greater reduction in HDL (versus
LDL) is probably reﬂected by a greater contribution of HDL to total
cholesterol in rats and suggests underlying perturbation of cho-
lesterol metabolism/excretion/absorption. This speculation is sup-
ported by decreased total cholesterol and, importantly, LDL in GS
(Table 1), which forms the greatest component of total cholesterol
in humans. Interestingly, hypocholesterolemia in the Gunn rat was
accompanied by signiﬁcantly decreased body mass (Table 2).
Therefore, it would seem reasonable to speculate that the pertur-
bation of lipid metabolism associated with elevated bilirubin (or
reduced UGT1A1 activity) is species independent and responsible
for reduced body mass in Gunn rats and BMI in human studies
[49,50]. These ﬁndings will encourage investigations exploring
how bilirubin modulates lipid metabolism, which could further
explain protection from ischemic heart disease in GS [10].
Bilirubin may also impart protection from atherosclerosis by
attenuating endothelial dysfunction [52] in response to oxidative
stress and inﬂammation. Interestingly, increased expression of
heme-oxygenase (HO-1) would degrade more heme and generate
more bilirubin in rabbit atherosclerotic lesions [53]. Circulating
heme concentrations were not signiﬁcantly elevated in the GS group
of this study and suggest that HO-1 is not responsible for the
cardiovascular protection in GS. However, bilirubin also accumulates
in foam cells [53], which suggests elevated bilirubin could protect
plasma [5] and LDL [42] from oxidation in atherosclerotic plaques,
where copper [54] accumulates. Together multiple beneﬁcial effects
of bilirubin may exist and explain the remarkably decreased risk of
CVD in GS, in addition to novel conclusions presented here.
In conclusion, these data show that elevated circulating
bilirubin is associated with improved circulating thiol status
and hypocholesterolemia, which could protect from atherosclero-
sis in GS via the ‘‘response to retention’’ and ‘‘oxidation modiﬁca-
tion’’ hypotheses [55]. The possible mechanisms responsible for
these effects represent a very novel and important avenue for
future research. The search for safe partial inhibitors of UGT1A1
that cause mildly elevated circulating unconjugated bilirubin
concentrations could support current efforts to induce a GS
phenotype [56,57] for translation into the clinic [9].Acknowledgments
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